First product is selling very well +47% yoy sales growth, NDA for second product expected in Q3 for NASH ! The chance to first to market with a NASH drug is a huge opportunity.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.